Table 4

Univariate and multivariate analysis of all covariates for prostate cancer risk, including established risk factors, 11 candidate genes, and IGF-1/IGFBP-3 levels

CovariateCrude odds ratio95% confidence intervalPAdjusted odds ratioa95% confidence intervalP
Established risk factors
 Age (continuous, per year)1.041.0–1.10.00011.041.0–1.10.0001
 PSA level (ng/ml)
  <10.01.001.00
  10.1–20.01.401.1–1.80.011.150.8–1.60.37
  >20.02.761.7–4.40.00011.781.1–3.00.03
 Free:Total PSA ratio
  >0.171.001.00
  0.12–0.172.141.4–3.40.0012.401.5–3.80.0003
  0.07–0.113.922.6–6.00.00014.833.1–7.60.0001
  <0.075.563.7–8.50.00016.684.2–10.60.0001
 Digital rectal exam
  Normal1.001.00
  Assymetry1.431.1–1.90.021.651.2–2.30.004
  Nodule2.111.5–2.90.00012.361.7–3.30.0001
 Ethnic background
  White1.001.00
  Black1.070.7–1.70.760.990.6–1.60.97
  Asian0.270.1–0.50.00010.270.1–0.50.0002
 Family history
  Absent1.001.00
  Present1.260.9–1.80.221.330.9–2.00.17
 Obstructive voiding symptoms
  Absent1.001.00
  Present0.800.6–1.10.150.880.6–1.20.45
Genetic risk factors
 SRD5A2
  VV1.001.00
  V/L0.840.6–1.10.180.860.6–1.30.28
  L/L0.760.5–1.10.220.970.6–1.60.89
 Androgen receptorb
  >18 CAG repeats1.001.00
  ≤18 CAG repeats0.970.7–1.40.891.070.7–1.60.73
 CYP17
  A1/A11.001.00
  A1/A20.980.8–1.30.900.850.6–1.10.29
  A2/A20.850.6–1.20.380.840.6–1.30.40
 CYP3A4
  WW1.001.00
  WV1.060.7–1.60.781.030.6–1.70.90
  VV1.000.5–1.80.990.730.3–1.70.48
 PSA
  AA1.001.00
  AG0.890.7–1.20.400.930.7–1.30.66
  GG0.850.6–1.20.320.860.6–1.20.41
 VDR
  bb1.001.00
  Bb0.980.7–1.40.890.990.7–1.40.97
  BB1.030.8–1.40.841.090.8–1.50.63
 GST-T1
  01.001.00
  11.320.9–1.80.071.340.9–1.90.09
 GST-M1
  01.001.00
  10.940.8–1.20.590.910.7–1.20.42
 GST-P1
  IL/IL1.001.00
  IL/V1.220.9–1.60.121.210.9–1.60.19
  VV1.300.8–2.20.331.280.7–2.30.41
 IGF-I
  No 19 allele1.001.00
  One 19 allele1.461.0–2.10.041.300.9–2.20.08
  Two 19 alleles1.581.1–2.30.021.460.9–1.90.20
 IGFBP-3
  AA1.001.00
  AC0.710.5–0.90.030.700.5–0.90.04
  CC1.000.7–1.30.980.900.6–1.20.52